Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension

2021 ◽  
Author(s):  
Ralf Ewert ◽  
Dirk Habedank ◽  
Michael Halank ◽  
Beate Stubbe ◽  
Christian F. Opitz
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Pulmonary Arterial ◽  
Prostacyclin Analog

scholarly journals Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

2018 ◽  
Vol 8 (3) ◽  
pp. 204589401879358 ◽  
Author(s):  
Martin Koestenberger ◽  
Georg Hansmann
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Children And Adolescents ◽  
Receptor Agonist ◽  
Off Label ◽  
Ip Receptor ◽  
Targeted Agent ◽  
Pulmonary Arterial ◽  
Prostacyclin Analog

We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy.

Sign in / Sign up

Export Citation Format

Share Document